A collection of engaging infographics from healthcare influencers that reveals trends in drug pipeline development;
A review of the biosimilar pipeline for products like Etanercept, Infliximab, Rituximab or Adalimumab reveals the breadth of hopeful treatments in late phase pipeline development. Via MedCity News from IMS.
Manufacturers face massive challenges in bringing a product to the market, with 95% of agents failing during development and only 20% making back their development investments. According to Dickson Data.
The pharma pipeline for cancer, cardiovascular diseases, diabetes and respiratory diseases is strong. As an example, there are close to 500 agents in the pipeline to treat cardiovascular diseases, according to IFPMA (International Federation of Pharmaceutical Manufacturers & Associations).
A recent infographic from Evolution shows a forecast of the biologic pipeline through 2019. Nearly half of these products are considered novel treatments, which translates to a higher probability of failure in some therapeutic areas.
Subscribe to the MMIT blog for more insights on trends affecting pharmaceutical manufacturers, providers and payers.